Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 9 (1) , 1730538
Abstract
CD40-stimulating immunotherapy can elicit potent anti-tumor responses by activating dendritic cells and enhancing T-cell priming. Tumor vessels orchestrate T-cell recruitment during immune response, but the effect of CD40-stimulating immunotherapy on tumor endothelial cells has not been evaluated. Here, we have investigated how tumor endothelial cells transcriptionally respond to CD40-stimulating immunotherapy by isolating tumor endothelial cells from agonistic CD40 mAb- or isotype-treated mice bearing B16-F10 melanoma, and performing RNA-sequencing. Gene set enrichment analysis revealed that agonistic CD40 mAb therapy increased interferon (IFN)-related responses in tumor endothelial cells, including up-regulation of the immunosuppressive enzyme Indoleamine 2, 3-Dioxygenase 1 (IDO1). IDO1 was predominantly expressed in endothelial cells within the tumor microenvironment, and its expression in tumor endothelium was positively correlated to T-cell infiltration and to increased intratumoral expression of IFNγ. In vitro, endothelial cells up-regulated IDO1 in response to T-cell-derived IFNγ, but not in response to CD40-stimulation. Combining agonistic CD40 mAb therapy with the IDO1 inhibitor epacadostat delayed tumor growth in B16-F10 melanoma, associated with increased activation of tumor-infiltrating T-cells. Hereby, we show that the tumor endothelial cells up-regulate IDO1 upon CD40-stimulating immunotherapy in response to increased IFNγ-secretion by T-cells, revealing a novel immunosuppressive feedback mechanism whereby tumor vessels limit T-cell activation.Keywords
Funding Information
- Barncancerfonden (PR2015-0133)
- Barncancerfonden (NCP2015-0075)
- Barncancerfonden (PR2018-0148)
- Barncancerfonden (TJ 2017-0004)
- Cancerfonden (CAN 2015/1216)
- Cancerfonden (CAN 2017/502)
- Emil och Wera Cornells Stiftelse (NA)
- FP7 International Cooperation (MCA-ITN 317445)
- Vetenskapsrådet (Dnr 2016-02495)
This publication has 53 references indexed in Scilit:
- TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusionsGenome Biology, 2013
- Genes2WordCloud: a quick way to identify biological themes from gene lists and free textSource Code for Biology and Medicine, 2011
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and HumansScience, 2011
- Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and InterpretationPLOS ONE, 2010
- Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceJournal of Clinical Investigation, 2010
- Indoleamine 2,3-Dioxygenase Tissue Distribution and Cellular Localization in Mice: Implications for Its Biological FunctionsJournal of Histochemistry & Cytochemistry, 2009
- Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodesBlood, 2009
- CD40Ig treatment results in allograft acceptance mediated by CD8+CD45RClow T cells, IFN-γ, and indoleamine 2,3-dioxygenaseJournal of Clinical Investigation, 2007
- Triggering CD40 on endothelial cells contributes to tumor growthJournal of Experimental Medicine, 2006
- BiNGO: a Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological NetworksBioinformatics, 2005